Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 4/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL183002 | 1.00 | CA4 (0.84) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL1303277 | 0.97 | CA4 (0.90) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL7004500 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL47867 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL445486 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL2974121 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL906010 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1FAHD1 | |
| Citric Acid SCHEMBL5471628 | 0.97 | CA4 (0.89) | CA4ALDH1A1CASP1 | |
| Citric Acid SCHEMBL22124526 | 0.95 | CA4 (0.85) | CA4CASP1FAHD1 | |
| Citric Acid SCHEMBL378980 | 0.94 | CA4 (0.84) | CA4ALDH1A1CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 491 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080107-A | Method for green extraction of glycyrrhizic acid | — | 2026-05-26 | — | — | CN | claimed |
| CN-122017257-A | Detection method and detection kit for oxidized low-density lipoprotein | 济南玖方生物科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | VIVAVISION BIOTECH LTD (CN) | 2026-03-05 | — | — | US | claimed |
| EP-4702973-A1 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| EP-4702974-A1 | OPHTHALMIC COMPOSITION CONTAINING VVN001 | Vivavision Biotech Ltd. (CN) | 2026-03-04 | — | — | EP | claimed |
| WO-2024221524-A9 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | 维眸生物科技(浙江)有限公司 | 2024-12-26 | — | — | WO | claimed |
| CN-119082249-A | Kit for detecting bone resorption, application of kit and preparation method of bone resorption detection material | 南方医科大学第三附属医院（广东省骨科研究院） | 2024-12-06 | — | — | CN | claimed |
| CN-118892446-A | Ophthalmic composition containing VVN001,001 | 维眸生物科技(浙江)有限公司 | 2024-11-05 | — | — | CN | claimed |
| CN-118892544-A | Ophthalmic composition for treating non-infectious inflammatory diseases | 维眸生物科技(浙江)有限公司 | 2024-11-05 | — | — | CN | claimed |
| WO-2024221524-A1 | OPHTHALMIC COMPOSITION FOR TREATING NON-INFECTIOUS INFLAMMATORY DISEASES | 维眸生物科技(浙江)有限公司 | 2024-10-31 | — | — | WO | claimed |
| US-20010032022-A1 | Surgical implant system,article and kit | HENRY SCHEIN, INC. | 2001-10-18 | — | — | US | claimed |
| EP-1124567-A2 | BUFFERED COMPOSITIONS FOR DIALYSIS | Advanced Renal Technologies (US) | 2001-08-22 | — | — | EP | claimed |
| US-6224635-B1 | Implantation of surgical implants with calcium sulfate | HOSPITAL FOR JOINT DISEASES | 2001-05-01 | — | — | US | claimed |
| US-6124350-A | PAINT CONTAINING A BIOCIDAL COMPOSITION COMPRISING A HALOPROPYNYL COMPOUND AND A BUFFER | TROY TECHNOLOGY CORPORATION, INC. (US) | 2000-09-26 | — | — | US | claimed |
| WO-2000027316-A1 | IMPLANTATION OF SURGICAL IMPLANTS WITH CALCIUM SULFATE | RICCI JOHN (US) | 2000-05-18 | — | — | WO | claimed |
| WO-2000023086-A2 | BUFFERED COMPOSITIONS FOR DIALYSIS | ADVANCED RENAL TECHNOLOGIES (US) | 2000-04-27 | — | — | WO | claimed |
| US-6017955-A | A BUFFER STABILIZER FOR ADJUSTING THE PH OF END-USE FORMULATION BETWEEN 3.0 AND 8.0 TO PREVENT DEGRADATION OF PESTICIDE 3-IODO-2-PROPYNYL BUTYL CARBAMATE | TROY TECHNOLOGY CORPORATION, INC. (US) | 2000-01-25 | — | — | US | claimed |
| EP-0831706-A1 | METHOD OF STABILIZING BIOCIDAL COMPOSITIONS OF HALOALKYNYL COMPOUNDS | TROY CHEMICAL CORPORATION (US) | 1998-04-01 | — | — | EP | claimed |
| WO-1996039836-A1 | METHOD OF STABILIZING BIOCIDAL COMPOSITIONS OF HALOALKYNYL COMPOUNDS | TROY CHEMICAL COMPANY (US) | 1996-12-19 | — | — | WO | claimed |
| US-4824664-A | ANTIHISTAMINES | LABORATOIRES SMITH KLINE & FRENCH (FR) | 1989-04-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060973-A1 | Ophthalmic Composition for Treating Non-Infectious Inflammatory Diseases | JAK1, TYK2, JAK3 | CA4 3086/4885ALDH1A1 2996/4885CASP1 877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.